PCSAProcessa Pharmaceuticals, Inc.vs its industry peers
A metric-by-metric comparison of Processa Pharmaceuticals, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PCSAThis | $5M#8 | 2.9x#3 | — | — | — | 214.5%#1 | — | — | — | — | -62.5%#4 | 0.8%#1 |
| BOLT | $7M#2 | — | 0.6x#3 | 0.9x#4 | 0.1%#6 | 47.1%#5 | -469.3%#7 | -264.1%#9 | — | — | -28.8%#1 | — |
| SYBX | $7M#3 | — | 0.6x#4 | — | -100.0%#9 | 95.7%#2 | — | -8.4%#3 | — | — | -63.8%#5 | — |
| ENVB | $7M#4 | — | 0.8x#5 | 0.2x#2 | -7.2%#7 | 26.0%#10 | -22.0%#2 | 149.7%#1 | -100.4%#2 | 3#2 | -80.0%#8 | — |
| ERNA | $6M#5 | 0.1x#1 | 2.0x#9 | 11.0x#8 | 755.9%#1 | 68.4%#4 | -1601.2%#8 | -440.1%#10 | -1016.2%#5 | — | -87.4%#9 | — |
| PULM | $5M#9 | — | 2.0x#10 | 0.7x#3 | 7.0%#4 | 46.0%#6 | -66.2%#3 | -201.9%#7 | -235.7%#3 | — | -71.6%#6 | — |
| XBIO | $5M#7 | — | 0.9x#6 | 1.8x#7 | 19.0%#2 | 32.3%#9 | -95.2%#4 | -44.1%#5 | -1516.8%#6 | 4#1 | -30.7%#2 | — |
| LABT | $5M#10 | — | 1.2x#7 | — | — | — | — | 0.0%#2 | — | — | — | — |
| PRPH | $6M#6 | — | — | 1.3x#5 | -35.8%#8 | 72.4%#3 | -415.4%#6 | — | -804.6%#4 | — | -91.6%#10 | — |
| DRMA | $5M#11 | — | 1.3x#8 | — | — | 38.5%#7 | — | -216.7%#8 | — | — | -79.5%#7 | — |
| RVPH | $5M#12 | — | 0.3x#2 | — | — | 33.6%#8 | — | -130.6%#6 | — | — | -95.5%#12 | — |
| INM | $8M#1 | — | 7.3x#11 | 1.6x#6 | 7.5%#3 | -53.9%#12 | -160.8%#5 | -1168.4%#11 | — | — | -40.1%#3 | — |
| SBFM | $4M#13 | 0.2x#2 | 0.1x#1 | 0.1x#1 | 4.1%#5 | -16.4%#11 | -17.2%#1 | -21.7%#4 | -63.1%#1 | — | -93.1%#11 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice